Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Sponsors
Dr Pragyan Paramita Bairisal
Eligibility
Inclusion criteria
Inclusion criteria: Treatment naive newly diagnosed Type 2 Diabetes Mellitus patients as per ADA criteria. HbA1c more than or equal to 6.5 Patients receiving either combination of metformin 1000mg per day plus sitagliptin 100mg per day or combination of metformin 1000mg per day plus dapagliflozin 10mg per day. Subjects who have given consent
Exclusion criteria
Exclusion criteria: History of drug allergy to metformin/dapagliflozin/sitagliptin. Other types of clinical diabetes. Pregnancy/Breastfeeding or those contemplating pregnancy in women of reproductive age group. Patients with acute metabolic decompensation such as Hyperglycemic hyperosmolar state /Diabetic ketoacidosis Patients with Chronic kidney disease, Chronic liver disease, coronary artery disease or Stroke within preceding 6 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate and compare glycemic control of group taking metformin and dapagliflozin combination with group taking metformin and sitagliptin combination as determined by reduction in HbA1c . Timepoint: Baseline HbA1c at zero week and 12 week will be recorded and compared | — |
Secondary
| Measure | Time frame |
|---|---|
| 1- To assess the lipid profile and weight changes. Timepoint: Baseline(0 week) and 12 weeks;To assess the adverse effects of the drugsTimepoint: Baseline (0 week) till 12 weeks | — |
Countries
India
Contacts
Public ContactDr PRAGYAN PARAMITA BAIRISAL
Institute of Medical Science And SUM Hospital
Outcome results
None listed